Advocacy intelligence hub — real-time data for patient organizations
Ain Shams University
University of North Carolina, Chapel Hill
Novartis Pharmaceuticals — PHASE2
Boston Medical Center — NA
Brooke Army Medical Center — NA
The University of Texas at Dallas — NA
Relay Therapeutics, Inc. — PHASE2
University of Calgary — NA
National Cancer Centre, Singapore
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Vijoice
Novartis Pharmaceuticals Corporation
Vijoice
(alpelisib)Orphan drugNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. Gain-...
Leslie G Biesecker, M.D., MD
National Human Genome Research Institute (NHGRI)
📍 BETHESDA, MD
Guillaume Canaud, MD,PHD
Institut National de la Santé Et de la Recherche Médicale, France
Gillian Gresham, MS, CCC-SLP/L
Cedars-Sinai Medical Center
📍 HOPEDALE, IL
James W. Griffith
University of Chicago